Pfizer (NYSE:PFE) signaled its intent to increase its COVID-19 vaccine price to roughly $110 to $130 per dose after the U.S. government’s purchase program for the vaccine expires, according to Angela Lukin, Pfizer’s global primary care and U.S. president.
The COVID-19 vaccine price hike would pertain to patients 12 and older.
The company could revise the pricing for the vaccine in the first quarter of 2023, assuming the U.S. government transitions COVID-19 vaccination to the private sector by then.
The U.S. government currently pays about $30 per dose for the COVID-19 vaccine from Pfizer and BioNTech (Nasdaq: BNTX).
Pfizer anticipates that private payers would cover the cost of the shots, making them free or nearly so for most individuals.
Demand for COVID-19 vaccines has fallen considerably in 2022, which could compel makers of COVID-19 vaccines to hike prices to meet revenue targets.
Pfizer ultimately anticipates the si…